Industry News

Aptevo Therapeutics recently announced patient-reported data on individuals currently being treated with IXINITY®, the company’s recombinant factor IX product.

The submission was based on positive results from a multi-stage clinical trial program which included more than 250 children and adults with hemophilia A worldwide

The medication is indicated for on-demand treatment and control of bleeding episodes.

Update: Shire has issued a new statement regarding the injunction.
In the past few weeks, we have received many inquiries regarding the scope of the injunction Shire is seeking in its lawsuit against Genentech/Roche.

Medscape recently launched a new education opportunity for healthcare providers.

BioMarin provided a series of updates on their investigational hemophilia A gene therapy candidate valoctocogene roxaparvovec.

The FDA has lifted a hold on clinical studies involving the investigational therapy fitusiran.

This agreement allows Shire to conduct research on the use of Rani Pill^™ technology for the oral delivery of factor VIII therapy for patients with hemophilia A.